Treatment-emergent effects may predict benefit from endocrine therapy.
Henry, N Lynn; Stearns, Vered.
J Clin Oncol
; 31(18): 2233-5, 2013 Jun 20.
Artigo em Inglês | MEDLINE | ID: mdl-23610120
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Adjuvant ovarian suppression in premenopausal breast cancer.
Extended Endocrine Therapy: Is 5 Years Enough?
Toremifene versus tamoxifen for advanced breast cancer.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer.
A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Determinants of non-adherence to adjuvant endocrine treatment in women with breast cancer: the role of comorbidity.